Featured

MiTEs turn TAM suppression into T cell synergy

Inhibition or reprogramming of tumor-associated macrophages (TAMs) has great potential to improve the tumor immune environment, but has, so far, shown limited clinical efficacy. To improve macrophage-targeted therapies, von Locquenghien, Zwicky, Cie...

A modular mRNA platform for programmable induction of tumor-specific immunogenic cell death

Dong et al. encoded the ICD-inducing protein 4HB in LNPs optimized for tumor cell specificity and hepatocyte avoidance, which significantly improved tumor cargo expression compared to a clinical contr...

CD8+ T cell antitumor immunity via human iNKT-DC conjugates

Baiu et al. showed that CD4+ invariant natural killer T cells (iNKT) and autologous or allogeneic monocyte-derived DCs formed stable complexes, with enhanced expression of MHC I, 4-1BBL, OX40L, and IL...

IL-9 as a naturally orthogonal cytokine with optimal JAK/STAT signaling for engineered T cell therapy

Taking advantage of low IL-9R expression in normal tissues, Jiang et al. engineered T cells with wild-type IL-9R. After transfer into tumor-bearing mice in combination with IL-9, which was well tolera...

Intratumoral three-cell-type clusters are a conserved feature of endogenous antitumor immunity

Damle and Carter et al. integrated spatial proteomics, tissue microarray, multiplex immunofluorescence imaging, and transcriptomics data from highly desmoplastic fibrolamellar carcinoma, and identifie...

See all for this week

Previous Digests

SITC - 40th Anniversary Annual Meeting 2025

November 19, 2025

The ACIR team attended the SITC - 40th Anniversary Annual Meeting 2025 in National Harbor, Maryland. This week’s extensive special feature covers select talks from the conference. We have organized the content by topics below. Keynote addressJennifer A. Wargo...

N17350: a cytotoxic cancer therapy that spares the immune system

November 12, 2025

Cytotoxic cancer treatments, like chemotherapy and radiation, have the potential to synergize with immunotherapies through direct killing of tumor cells, which leads to the release of antigens and damage-associated molecular patterns. However, this potential synergy is often hindered when...

COVID-19 mRNA vaccines provide a surprising boost to ICB therapy efficacy

November 5, 2025

Improving the efficacy of immune checkpoint blockade (ICB) for a larger group of patients, particularly those with immune-cold tumors, is one of the major goals of current immunotherapy research. Based on case reports of patients who had spontaneous tumor...

See More Digests

Watch ACIR in action

In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.

Watch the 3-minute video explaining ACIR's mission and goal:

In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.

Watch the 6-minute segment on the story behind your favorite digest here:

Donate to support researchers

About ACIR

ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.

Ute Burkhardt

Ed Fritsch

Lauren Hitchings

Gaelle Llambi

Maartje Wouters

Alex Najibi

Katherine J. Turner

Stan Wolf

Paula Hochman

Shishir Pant

Nathan Suek

Morgan Janes

More About Us

TESTIMONIALS

I'm a big fan of ACIR. I enjoy their weekly newsletters with clear, concise, and insightful summaries, complemented by excellent images. I've even used the images in some of my presentations to explain complex cancer immunotherapy findings. In our rapidly evolving field, their reliable and well-curated updates are invaluable.

— Carl H. June, MD

Richard W. Vague Professor in Immunotherapy; Professor of PL&M; Director, Center for Cellular Immunotherapies; Director, Parker Institute for Cancer Immunotherapy; University of Pennsylvania Perelman School of Medicine. (Supporter since 2025).

Testimonials